{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:01:07Z","timestamp":1791234067403,"version":"4.1.0"},"reference-count":61,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Infantile haemangioma (IH) remains the most common benign vascular tumour in childhood. Although most IH can be managed conservatively, a proportion of these lesions can cause disfigurement, ulceration or functional impairment, requiring prompt intervention. Propranolol, a lipophilic nonselective beta blocker, has been regarded as first-line therapy, following a serendipitous discovery of its use for IH in 2008. Although efficacious, it has been associated with adverse effects such as hypoglycaemia, bronchospasm, sleep disturbances and agitation in infant trials. Atenolol, a hydrophilic beta-1 selective blocker, has demonstrated similar efficacy and potentially greater tolerability, being less likely to cause sleep disturbances given its inability to cross the blood\u2013brain barrier, and a decrease in bronchial reactivity. The purpose of this review is to explore and critique current knowledge about the efficacy and safety of propranolol vs. atenolol in children with an IH. In total, seven studies comparing the two beta blockers were identified in our search. Atenolol appeared to be as efficacious as propranolol and was associated with fewer central nervous system and bronchial-related adverse events. Further research exploring the optimal dosing for atenolol, particularly for ulcerated or syndromic IHs, as well as the incidence and management of rebound growth would be beneficial.<\/jats:p>","DOI":"10.1093\/ced\/llae401","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T15:25:28Z","timestamp":1728055528000},"page":"331-338","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and safety of atenolol vs. propranolol for treatment of infantile haemangioma: a narrative review"],"prefix":"10.1093","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9219-5252","authenticated-orcid":false,"given":"Michelle","family":"Shi","sequence":"first","affiliation":[{"name":"School of Women\u2019s and Children\u2019s Health, University of New South Wales , Sydney, NSW ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orli","family":"Wargon","sequence":"additional","affiliation":[{"name":"Department of Paediatric Dermatology, Sydney Children\u2019s Hospital Randwick , Randwick, NSW ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artiene","family":"Tatian","sequence":"additional","affiliation":[{"name":"Department of Paediatric Dermatology, Sydney Children\u2019s Hospital Randwick , Randwick, NSW ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,4]]},"reference":[{"key":"2025012715560436700_llae401-B1","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1525-1470.2008.00626.x","article-title":"Infantile hemangiomas: how common are they? A systematic review of the medical literature","volume":"25","author":"Kilcline","year":"2008","journal-title":"Pediatr Dermatol"},{"key":"2025012715560436700_llae401-B2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0140-6736(16)00645-0","article-title":"Infantile haemangioma","volume":"390","author":"L\u00e9aut\u00e9-Labr\u00e8ze","year":"2017","journal-title":"Lancet"},{"key":"2025012715560436700_llae401-B3","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1542\/peds.2012-1691","article-title":"Initiation and use of propranolol for infantile hemangioma: report of a consensus conference","volume":"131","author":"Drolet","year":"2013","journal-title":"Pediatrics"},{"key":"2025012715560436700_llae401-B4","doi-asserted-by":"crossref","first-page":"e1060","DOI":"10.1542\/peds.2015-2485","article-title":"Diagnosis and management of infantile hemangioma","volume":"136","author":"Darrow","year":"2015","journal-title":"Pediatrics"},{"key":"2025012715560436700_llae401-B5","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1056\/NEJMc0708819","article-title":"Propranolol for severe hemangiomas of infancy","volume":"358","author":"L\u00e9aut\u00e9-Labr\u00e8ze","year":"2008","journal-title":"N Engl J Med"},{"key":"2025012715560436700_llae401-B6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/ajd.12966","article-title":"Efficacy and safety of oral atenolol for the treatment of infantile haemangioma: a systematic review","volume":"60","author":"Wang","year":"2019","journal-title":"Australas J Dermatol"},{"key":"2025012715560436700_llae401-B7","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.3892\/etm.2020.8842","article-title":"Atenolol vs. propranolol for the treatment of infantile haemangiomas: a systematic review and meta-analysis","volume":"20","author":"Liu","year":"2020","journal-title":"Exp Ther Med"},{"key":"2025012715560436700_llae401-B8","author":"International Society for the Study of Vascular Anomalies"},{"key":"2025012715560436700_llae401-B9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/229255031302100103","article-title":"Beta-blockers for the treatment of problematic hemangiomas","volume":"21","author":"Sharma","year":"2013","journal-title":"Can J Plast Surg"},{"key":"2025012715560436700_llae401-B10","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.jaad.2021.08.019","article-title":"Infantile hemangioma. Part 1: epidemiology, pathogenesis, clinical presentation and assessment","volume":"85","author":"Bandera AI","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2025012715560436700_llae401-B11","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s12519-019-00327-2","article-title":"Risk factors for infantile hemangioma: a meta-analysis","volume":"16","author":"Ding","year":"2020","journal-title":"World J Pediatr"},{"key":"2025012715560436700_llae401-B12","doi-asserted-by":"crossref","first-page":"43292","DOI":"10.1038\/srep43292","article-title":"When to stop propranolol for infantile hemangioma","volume":"7","author":"Chang","year":"2017","journal-title":"Sci Rep"},{"key":"2025012715560436700_llae401-B13","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1136\/jcp.2010.079368","article-title":"Primitive mesodermal cells with a neural crest stem cell phenotype predominate proliferating infantile haemangioma","volume":"63","author":"Itinteang","year":"2010","journal-title":"J Clin Pathol"},{"key":"2025012715560436700_llae401-B14","doi-asserted-by":"crossref","first-page":"610758","DOI":"10.3389\/fsurg.2020.610758","article-title":"Cell populations expressing stemness-associated markers in vascular anomalies","volume":"7","author":"Kilmister","year":"2020","journal-title":"Front Surgery"},{"key":"2025012715560436700_llae401-B15","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/jclinpath-2011-200191","article-title":"A placental chorionic villous mesenchymal core cellular origin for infantile haemangioma","volume":"64","author":"Itinteang","year":"2011","journal-title":"J\u00a0Clin Pathol"},{"key":"2025012715560436700_llae401-B16","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1001\/archdermatol.2010.1295","article-title":"Characteristics of infantile hemangiomas as clues to pathogenesis: does hypoxia connect the dots?","volume":"146","author":"Drolet","year":"2010","journal-title":"Arch Dermatol"},{"key":"2025012715560436700_llae401-B17","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/pde.13626","article-title":"Localized infantile hemangiomas of the face and scalp: predilection for the midline and periorbital and perioral skin","volume":"35","author":"Haggstrom","year":"2018","journal-title":"Pediatr Dermatol"},{"key":"2025012715560436700_llae401-B18","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.jaad.2021.08.020","article-title":"Infantile hemangioma. Part 2: management","volume":"85","author":"Sebaratnam","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2025012715560436700_llae401-B19","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3109\/02841868709092974","article-title":"Radiation therapy of hemangiomas, 1909\u20131959. A cohort based on 50\u2005years of clinical practice at Radiumhemmet, Stockholm","volume":"26","author":"F\u00fcrst","year":"1987","journal-title":"Acta Oncol"},{"key":"2025012715560436700_llae401-B20","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1055\/s-2006-949118","article-title":"Surgery: the treatment of choice for hemangiomas","volume":"20","author":"Boyd","year":"2006","journal-title":"Semin Plast Surg"},{"key":"2025012715560436700_llae401-B21","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1001\/archoto.2011.207","article-title":"Surgical management of auricular infantile hemangiomas","volume":"138","author":"Daramola","year":"2012","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"2025012715560436700_llae401-B22","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1001\/archderm.137.9.1208","article-title":"Oral corticosteroid use is effective for cutaneous hemangiomas: an evidence-based evaluation","volume":"137","author":"Bennett","year":"2001","journal-title":"Arch Dermatol"},{"key":"2025012715560436700_llae401-B23","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1001\/archdermatol.2011.203","article-title":"Propranolol vs corticosteroids for infantile hemangiomas: a multicenter retrospective analysis","volume":"147","author":"Price","year":"2011","journal-title":"Arch Dermatol"},{"key":"2025012715560436700_llae401-B24","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/bjd.12217","article-title":"Double-blind randomized pilot trial evaluating the efficacy of oral propranolol on infantile haemangiomas in infants\u00a0&lt;\u00a04\u2005months of age","volume":"169","author":"L\u00e9aut\u00e9-Labr\u00e8ze","year":"2013","journal-title":"Br J Dermatol"},{"key":"2025012715560436700_llae401-B25","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa1404710","article-title":"A randomized, controlled trial of oral propranolol in infantile hemangioma","volume":"372","author":"L\u00e9aut\u00e9-Labr\u00e8ze","year":"2015","journal-title":"N Engl J Med"},{"key":"2025012715560436700_llae401-B26","doi-asserted-by":"crossref","first-page":"e259","DOI":"10.1542\/peds.2010-0029","article-title":"A randomized controlled trial of propranolol for infantile hemangiomas","volume":"128","author":"Hogeling","year":"2011","journal-title":"Pediatrics"},{"key":"2025012715560436700_llae401-B27","doi-asserted-by":"crossref","first-page":"e43026","DOI":"10.7554\/eLife.43026","article-title":"R-propranolol is a small molecule inhibitor of the SOX18 transcription factor in a rare vascular syndrome and hemangioma","volume":"8","author":"Overman","year":"2019","journal-title":"eLife"},{"key":"2025012715560436700_llae401-B28","doi-asserted-by":"crossref","first-page":"e151109","DOI":"10.1172\/JCI151109","article-title":"Non-beta blocker enantiomers of propranolol and atenolol inhibit vasculogenesis in infantile hemangioma","volume":"132","author":"Seebauer","year":"2022","journal-title":"J Clin Invest"},{"key":"2025012715560436700_llae401-B29","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/PRS.0000000000007699","article-title":"Propranolol therapy in infantile hemangioma: it is not just about the beta","volume":"147","author":"Lee","year":"2021","journal-title":"Plast Reconstr Surg"},{"key":"2025012715560436700_llae401-B30","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/bjd.13388","article-title":"The use of propranolol in the treatment of infantile haemangiomas: an update on potential mechanisms of action","volume":"172","author":"Ji","year":"2015","journal-title":"Br J Dermatol"},{"key":"2025012715560436700_llae401-B31","doi-asserted-by":"crossref","first-page":"e3908","DOI":"10.1097\/MD.0000000000003908","article-title":"Oral atenolol therapy for proliferating infantile hemangioma: a prospective study","volume":"95","author":"Ji","year":"2016","journal-title":"Medicine (Baltimore"},{"key":"2025012715560436700_llae401-B32","doi-asserted-by":"crossref","first-page":"116","DOI":"10.21037\/atm-20-5359","article-title":"Oral atenolol treatment for infantile hemangiomas: clinical analysis of 133 consecutive patients","volume":"9","author":"Zhao","year":"2021","journal-title":"Ann Transl Med"},{"key":"2025012715560436700_llae401-B33","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jaad.2014.01.905","article-title":"Atenolol versus propranolol for the treatment of infantile hemangiomas: a randomized controlled study","volume":"70","author":"\u00c1barz\u00faa-Araya","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"2025012715560436700_llae401-B34","author":"Ashraf"},{"key":"2025012715560436700_llae401-B35","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1001\/jamaoto.2021.0454","article-title":"Efficacy and safety of propranolol vs atenolol in infants with problematic infantile hemangiomas: a randomized clinical trial","volume":"147","author":"Ji","year":"2021","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"2025012715560436700_llae401-B36","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/j.bjps.2013.07.035","article-title":"Treatment of infantile haemangiomas with atenolol: comparison with a historical propranolol group","volume":"66","author":"de Graaf","year":"2013","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"2025012715560436700_llae401-B37","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/pde.13177","article-title":"Atenolol versus propranolol for treatment of infantile hemangiomas during the proliferative phase: a retrospective noninferiority study","volume":"34","author":"Bayart","year":"2017","journal-title":"Pediatr Dermatol"},{"key":"2025012715560436700_llae401-B38","doi-asserted-by":"crossref","first-page":"e199","DOI":"10.1111\/jdv.15464","article-title":"Atenolol treatment for severe infantile hemangiomas: comparison with a propranolol group of our centre","volume":"33","author":"Dakoutrou","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025012715560436700_llae401-B39","doi-asserted-by":"crossref","first-page":"adv00788","DOI":"10.2340\/actadv.v102.2021","article-title":"Aesthetic outcome of propranolol vs atenolol treatment of children with infantile haemangioma","volume":"102","author":"Hermans","year":"2022","journal-title":"Acta Derm Venereol"},{"key":"2025012715560436700_llae401-B40","doi-asserted-by":"crossref","first-page":"e20183475","DOI":"10.1542\/peds.2018-3475","article-title":"Clinical practice guideline for the management of infantile hemangiomas","volume":"143","author":"Krowchuk","year":"2019","journal-title":"Pediatrics"},{"key":"2025012715560436700_llae401-B41","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/jpc.12720","article-title":"Low-dose propranolol regimen for infantile haemangioma","volume":"51","author":"Tan","year":"2015","journal-title":"J Paediatr Child Health"},{"key":"2025012715560436700_llae401-B42","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s40801-015-0052-3","article-title":"Therapeutic effect of propranolol in mexican patients with infantile hemangioma","volume":"3","author":"Castaneda","year":"2016","journal-title":"Drugs Real World Outcomes"},{"key":"2025012715560436700_llae401-B43","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/pde.14281","article-title":"Retrospective case series of increased oral propranolol dosage for infantile hemangiomas","volume":"37","author":"Huang","year":"2020","journal-title":"Pediatr Dermatol"},{"key":"2025012715560436700_llae401-B44","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1001\/jamadermatol.2021.0469","article-title":"Clinical features, prognostic factors, and treatment interventions for ulceration in patients with infantile hemangioma","volume":"157","author":"Faith E","year":"2021","journal-title":"JAMA Dermatol"},{"key":"2025012715560436700_llae401-B45","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1525-1470.2012.01879.x","article-title":"Propranolol use in PHACE \u00adsyndrome with cervical and intracranial arterial anomalies: \u00adcollective experience in 32 infants","volume":"30","author":"Metry","year":"2013","journal-title":"Pediatr Dermatol"},{"key":"2025012715560436700_llae401-B46","doi-asserted-by":"crossref","first-page":"279","DOI":"10.4103\/jiaps.jiaps_3_21","article-title":"Oral atenolol versus propranolol in the treatment of infantile hemangioma: a systematic review and meta-analysis","volume":"27","author":"Pattanshetti","year":"2022","journal-title":"J Indian Assoc Pediatr Surg"},{"key":"2025012715560436700_llae401-B47","first-page":"A4776","article-title":"Effectiveness of propanolol for treatment of infantile haemangioma","volume":"61","author":"Andersen","year":"2014","journal-title":"Dan Med J"},{"key":"2025012715560436700_llae401-B48","doi-asserted-by":"crossref","first-page":"e20151754","DOI":"10.1542\/peds.2015-1754","article-title":"Rebound growth of infantile hemangiomas after propranolol therapy","volume":"137","author":"Shah","year":"2016","journal-title":"Pediatrics"},{"key":"2025012715560436700_llae401-B49","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1177\/1060028013519591","article-title":"\u03b2-blockers: a review of their pharmacological and physiological diversity in hypertension","volume":"48","author":"Ripley","year":"2014","journal-title":"Ann Pharmacother"},{"key":"2025012715560436700_llae401-B50","first-page":"187","volume-title":"Frontiers in Computational Chemistry","author":"Karaman","year":"2015"},{"key":"2025012715560436700_llae401-B51","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jpra.2022.05.010","article-title":"Cost-effectiveness of atenolol compared to propranolol as first-line treatment of infantile haemangioma: a pilot study","volume":"33","author":"Wilson","year":"2022","journal-title":"JPRAS Open"},{"key":"2025012715560436700_llae401-B52","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/BF02524799","article-title":"Long-term efficacy and safety of atenolol for supraventricular tachycardia in children","volume":"17","author":"Mehta","year":"1996","journal-title":"Pediatr Cardiol"},{"key":"2025012715560436700_llae401-B53","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00246-003-0536-x","article-title":"Long-term efficacy of atenolol for atrioventricular reciprocating tachycardia in children less than 5\u2005years old","volume":"25","author":"Ko","year":"2004","journal-title":"Pediatr Cardiol"},{"key":"2025012715560436700_llae401-B54","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1177\/000348941112001010","article-title":"Status of propranolol for treatment of infantile hemangioma and description of a randomized clinical trial","volume":"120","author":"Menezes","year":"2011","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"2025012715560436700_llae401-B55","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-22787-8","article-title":"Intolerable side effects during propranolol therapy for infantile hemangioma: frequency, risk factors and management","volume":"8","author":"Ji","year":"2018","journal-title":"Sci Rep"},{"key":"2025012715560436700_llae401-B56","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/pde.12686","article-title":"Oral nadolol for children with infantile hemangiomas and sleep disturbances with oral propranolol","volume":"32","author":"Bernabeu-Wittel","year":"2015","journal-title":"Pediatr Dermatol"},{"key":"2025012715560436700_llae401-B57","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/pde.14484","article-title":"Propranolol's effects on the sleep of infants with hemangiomas: a prospective pilot study","volume":"38","author":"Frost","year":"2021","journal-title":"Pediatr Dermatol"},{"issue":"Suppl.","key":"2025012715560436700_llae401-B58","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/BF00543712","article-title":"Beta-blockers and sleep: a controlled trial","volume":"28","author":"Betts","year":"1985","journal-title":"Eur J Clin Pharmacol"},{"key":"2025012715560436700_llae401-B59","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/bjd.15317","article-title":"Atenolol treatment for infantile haemangioma","volume":"176","author":"Tasani","year":"2017","journal-title":"Br J Dermatol"},{"key":"2025012715560436700_llae401-B60","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/pde.13839","article-title":"Atenolol as an alternative to propranolol for the management of sleep disturbances in the treatment of infantile hemangiomas","volume":"36","author":"Gumina","year":"2019","journal-title":"Pediatr Dermatol"},{"key":"2025012715560436700_llae401-B61","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00431-022-04674-7","article-title":"Long-term neurocognitive functioning of children treated with propranolol or atenolol for infantile hemangioma","volume":"182","author":"Hermans","year":"2023","journal-title":"Eur J Pediatr"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llae401\/60751662\/llae401.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llae401\/60751662\/llae401.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llae401\/60751662\/llae401.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T15:56:46Z","timestamp":1737993406000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/2\/331\/7811067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,4]]},"references-count":61,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,10,4]]},"published-print":{"date-parts":[[2025,1,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llae401","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2024,10,4]]}}}